

REFERENCES

1. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010;25:603-605.
2. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-188.
3. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-560.
4. Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? *Gut* 2022;71:382-390.
5. Farrell AM, Magliano DJ, Shaw JE, Thompson AJ, Croagh C, Ryan MC, et al. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. *Sci Rep* 2022;12:1956.
6. Feldman A, Wernly B, Strebinger G, Eder SK, Zandanell S, Niederseer D, et al. Liver-related mortality is increased in lean subjects with non-alcoholic fatty liver disease compared to overweight and obese subjects. *J Gastrointest Liver Dis* 2021;30:366-373.
7. Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y, et al. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. *Hepatol Commun* 2022;6:3393-3405.
8. Nabi O, Lapidus N, Boursier J, de Ledinghen V, Petit JM, Kab S, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). *Hepatology* 2023;78:272-283.
9. Leung JC, Loong TC, Wei JL, Wong GL, Chan AW, Choi PC, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. *Hepatology* 2017;65:54-64.
10. Biswas S, Vaishnav M, Farooqui N, Aggarwal A, Pathak P, Yadav R, et al. Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease. *Postgrad Med J* 2023;99:1094-1103.
11. Hirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, et al. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. *PLoS One* 2020;15:e0241770.
12. Iritani S, Akuta N, Kawamura Y, Kajiwara A, Kasuya K, Fujiyama S, et al. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. *BMC Gastroenterol* 2020;20:368.
13. Kawanaka M, Nishino K, Kawada M, Ishii K, Tanikawa T, Katsumata R, et al. Lean nonalcoholic fatty liver disease: Age-dependent differences in pathology, prognosis, and liver-related events. *Hepatol Res* 2023;53:829-843.
14. Wakabayashi SI, Tamaki N, Kimura T, Umemura T, Kurosaki M, Izumi N. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. *J Gastroenterol* 2024;59:494-503.
15. Park MK, Hur MH, Moon HS, Shin H, Chung SW, Won S, et al. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study. *Liver Int* 2024;44:799-810.
16. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. *Hepatol Commun* 2017;2:48-57.
17. Charatcharoenwitthaya P, Karaketklang K, Aekplakorn W. Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease. *J Cachexia Sarcopenia Muscle* 2022;13:2393-2404.
18. Fan X, Shi Y, Han J, Song Y, Zhao J. Beyond body weight: Diversified presentation of MASLD in lean, overweight, and obese participants. *J Hepatol* 2024;80:e147-e150.
19. Cruz ACD, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P, et al. 379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. *Gastroenterology* 2014;146:S-909.
20. Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. *Hepatol Commun* 2020;4:1136-1148.
21. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. *J Intern Med* 2020;288:139-151.
22. Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with normal body mass index: A population-based study. *Clin Gastroenterol Hepatol* 2022;20:1374-1381.e6.
23. Behari J, Wang R, Luu HN, McKenzie D, Molinari M, Yuan JM. Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease. *Hepatol Commun* 2024;8:e0471.

24. Wijarnpreecha K, Li F, Lundin SK, Suresh D, Song MW, Tao C, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. *Aliment Pharmacol Ther* 2023;57:1014-1027.
25. Aneni EC, Bittencourt MS, Teng C, Cainzos-Achirica M, Osondu CU, Soliman A, et al. The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. *Am J Prev Cardiol* 2020;4:100097.
26. Yang C, Yang S, Feng C, Zhang C, Xu W, Zhang L, et al. Associations of hyperuricemia and obesity with remission of non-alcoholic fatty liver disease among Chinese men: A retrospective cohort study. *PLoS One* 2018;13:e0192396.
27. Li N, Xang W, Wu S, Li D, Chang M, Xie C, et al. Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period. *Front Endocrinol (Lausanne)* 2023;14:1173757.
28. Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. *Liver Int* 2016;36:275-283.
29. Wei L, Cheng X, Luo Y, Yang R, Lei Z, Jiang H, et al. Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study. *Diabetes Metab* 2021;47:101200.
30. Ishido S, Tamaki N, Takahashi Y, Uchihara N, Suzuki K, Tanaka Y, et al. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. *BMC Gastroenterol* 2023;23:211.
31. Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, et al. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. *Dig Liver Dis* 2018;50:370-377.
32. Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, et al. Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. *Eur J Endocrinol* 2019;181:185-192.
33. Chon YE, Kim HJ, Choi YB, Hwang SG, Rim KS, Kim MN, et al. Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease. *Sci Rep* 2020;10:8996.
34. Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. *Gut Liver* 2022;16:290-299.
35. Niriella MA, Kasturiratne A, Pathmeswaran A, De Silva ST, Perera KR, Subasinghe SKCE, et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. *Hepatol Int* 2019;13:314-322.
36. Arvind A, Henson JB, Osganian SA, Nath C, Steinhagen LM, Memel ZN, et al. Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease. *Hepatol Commun* 2022;6:309-319.
37. Dai H, Xiang J, Hou Y, Xuan L, Wang T, Li M, et al. Fat mass to fat-free mass ratio and the risk of non-alcoholic fatty liver disease and fibrosis in non-obese and obese individuals. *Nutr Metab (Lond)* 2021;18:21.